Scientist.com introduces new tool for clinical trial management
This tool helps streamline workflows, enhance communication, and promote transparency throughout the clinical research lifecycle.
It is tailored to meet the demands of life science organisations, offering a 'compliant and connected' workflow.
The navigator tool addresses several 'high impact' areas for both sponsors and contract research organisations (CROs).
They include budget digitisation, built-in cost modelling tools, improved audit trails, and analytics.
These advancements aim to refine budget accuracy, increase compliance.
The solution is especially beneficial for organisations looking to 'consolidate' sourcing efforts, minimise trial delay periods, and enhance visibility throughout worldwide clinical operations. It claims to remove the complex trial design's inefficiencies.
With this tool's introduction, the company broadens its clinical-stage portfolio, now providing solutions across the whole development pipeline.
This includes real-world evidence/data (RWE/RWD), health economics and outcomes research (HEOR), market access, good manufacturing practice (GMP) manufacturing, and late-stage biomarker development.
By utilising AI-enabled tools and embedded compliance frameworks, the platform enables procurement professionals and researchers to make quick decisions, thereby expediting the therapy development.
Scientist.com Compliance & Categories senior vice-president Matt McLoughlin said: 'Clinical Labs Navigator was built to meet the increasing need for integrated, efficient, and compliant solutions in clinical trial execution.
'We've created a tool that not only helps clients streamline the design of clinical trials, through enhanced internal and external collaboration, but increases transparency throughout the study design and contracting process.'
"Scientist.com introduces new tool for clinical trial management" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
Business Wire
2 days ago
- Business Wire
Bionova Scientific ® opens new pDNA facility in Texas to support rapidly growing biopharma industry
HOUSTON--(BUSINESS WIRE)--Bionova Scientific ®, a full-service biologics contract development and manufacturing organization (CDMO) and subsidiary of global conglomerate Asahi Kasei, has announced the opening of a 10,000 square-foot state-of-the-art plasmid DNA (pDNA) development and production facility in The Woodlands, Texas. Located less than 30 miles north of Houston, Texas, the new facility designs, develops and manufactures research-grade pDNA materials to support the cell and gene therapy field. With the global pharmaceutical market anticipated to reach almost $3 trillion by 2033, Bionova Scientific has positioned itself to effortlessly accommodate the market's rapid growth. Enabled by the new Texas facility, the company will expand its offerings beyond mammalian protein production and provide clinical to commercial-scale Current Good Manufacturing Practice (CGMP) production of pDNA by Q4 2025. Plasmid DNA is a critical starting material for advanced therapeutics, including mRNA and viral vector-based cell and gene therapies (CGTs). Adding pDNA development and manufacturing services enhances Bionova Scientific's established expertise in antibody and protein CDMO services, already offered via its recently expanded flagship facility in San Francisco's Bay Area. Through these added services, Bionova is broadening its portfolio across biotherapeutic modalities to serve more customers. This strategic expansion is not just about capacity, it's about evolving alongside the next generation of advanced therapy developers and meeting their unique needs with the same quality, flexibility, and scientific rigor that have defined Bionova's existing partnerships in protein development and GMP manufacturing out of Fremont, CA. 'Bionova added these highly sought-after pDNA capabilities in response to a persistent unmet need among the cell and gene therapy biopharma community. Completing this specialized facility on schedule is not only a milestone for our team, but a crucial step in ensuring our customers receive the reliable, timely support they need to meet their own deadlines,' commented Darren Head, President and Chair of Bionova. 'We chose The Woodlands because of its proximity to a growing number of CGT companies, and its location provides Bionova with access to the rapidly expanding CGT ecosystem here in the U.S. By aligning our capabilities with the needs of the CGT sector, we look forward to building lasting partnerships that accelerate the industry.' As a core growth driver within Asahi Kasei's Life Science group, Bionova continues to scale its presence to meet the evolving needs of the biopharmaceutical industry. Backed by Asahi Kasei's medium-term management plan, which prioritizes expansion across its virus filtration, CRO testing, and CDMO businesses, Bionova is positioned to lead in delivering high-impact solutions for next-generation therapies. The company's ongoing investments in specialized capabilities underscore its role at the forefront of Asahi Kasei Life Science's strategy. To learn more about Bionova Scientific, visit About Bionova Scientific Bionova Scientific partners with innovators in the biologic industry to bring life-changing therapies to market with a dedication to quality and service. Founded in 2014 and acquired by Asahi Kasei Group in 2022, Bionova Scientific offers our client partners access to advanced technological platforms, and a strong commitment to quality delivered with scientific excellence across the entire lifecycle of your drug product. As an integrated CDMO, Bionova provides services that span discovery through cGMP commercial supply of complex therapeutic proteins and antibodies. Our experienced scientists bring proven expertise to overcome discovery to first-in-human development challenges and enabling efficient and easy scale-up. In 2025, Bionova expanded its capabilities with the launch of a dedicated plasmid DNA (pDNA) development and manufacturing facility in Houston, Texas, further strengthening our position as a trusted partner in advanced therapy production. Bionova is a flexible and collaborative partner that has worked with leading biotechnology innovators from its new state-of-the-art facility in the San Francisco Bay Area. For more information, visit About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Healthcare, Homes, and Material. For more information, visit and
Time Business News
5 days ago
- Time Business News
Halal Certification in USA – Top 5 Providers You Can Trust
Halal certification in the USA is essential for businesses that want to serve Muslim consumers or access export markets where halal compliance is mandatory. With growing demand for halal products—from food and beverages to cosmetics and pharmaceuticals—choosing the right halal certifier can make or break your credibility. In this guide, we'll cover the top 5 halal certification providers in USA, with Halal Watch taking the number one spot for its trust, experience, and transparent process. Halal Watch World (HWW) is a leading U.S.-based halal certification provider with over 40 years of experience serving businesses across various industries. Recognized nationwide for its clear process and commitment to authenticity, HWW has built long-term trust among Muslim consumers and retailers. Halal certification for food, beverages, cosmetics, nutraceuticals, and pharmaceuticals. Assistance with halal labeling compliance to meet U.S. regulations. Option to combine halal audits with other certifications like SQF, Vegan, Non-GMO, and GMP. Decades of proven industry experience. Fast, efficient certification process. Recognized across the USA for retail acceptance. 💡 Best For: U.S. businesses that want credible, accessible halal certification to boost sales and consumer trust. IFANCA is one of the most established halal certifiers in the world, with a strong global presence and partnerships with multinational brands. What They Offer: Certification for food, ingredients, and cosmetics. International recognition for exports. Best For: Manufacturers targeting global export markets. ISA is highly respected for meat and poultry certification and has strong expertise in slaughterhouse operations. What They Offer: Halal audits for slaughterhouses, meat processors, and packaged foods. Support for export compliance. Best For: Meat and poultry companies or exporters. AHF offers halal certification with a focus on ISO/17065 compliance and international standards. What They Offer: Certification across multiple sectors. Export credibility for various markets. Best For: Brands seeking ISO-compliant halal certification for international trade. HFSAA caters to Muslim communities that prefer hand-slaughtered (zabiha) products and stricter halal interpretations. What They Offer: Certification for restaurants, meat processors, and packaged goods. Transparent halal standards. Best For: Businesses targeting strict halal consumer segments. When deciding on a halal certification provider, consider: Target Market – Domestic, export, or both. Slaughter Method Requirements – Hand-slaughter vs. machine-slaughter preferences. Accreditations – Check if your target country recognizes the certifier. Scope – Not all certifiers handle cosmetics, supplements, or pharmaceuticals. ✅ Pro Tip: If your main audience is in the USA, start with Halal Watch for credibility in domestic retail. For export, you can add a second certification from IFANCA or ISA for broader acceptance. TIME BUSINESS NEWS
